4//SEC Filing
Davis George Eric 4
Accession 0001048477-24-000075
CIK 0001048477other
Filed
May 5, 8:00 PM ET
Accepted
May 6, 4:45 PM ET
Size
10.3 KB
Accession
0001048477-24-000075
Insider Transaction Report
Form 4
Davis George Eric
VP, General Counsel
Transactions
- Award
Common Stock
2024-04-30$68.65/sh+301$20,662→ 56,157 total - Exercise/Conversion
Common Stock
2024-05-02$63.10/sh+1,850$116,735→ 58,007 total - Exercise/Conversion
Stock Option (Right to Buy Common Stock)
2024-05-02−1,850→ 40,850 totalExercise: $63.10From: 2014-12-04Exp: 2024-06-30→ Common Stock (1,850 underlying) - Sale
Common Stock
2024-05-02$85.01/sh−1,850$157,269→ 56,157 total
Footnotes (4)
- [F1]Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan.
- [F2]Trade made pursuant to a 10b5-1 plan executed on September 13, 2023.
- [F3]The price in column 4 is the weighted average price. The purchase price actually received ranged from $85.00 to $85.03. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- [F4]Reflects the number of options outstanding after the transactions from this specific stock option grant.
Documents
Issuer
BIOMARIN PHARMACEUTICAL INC
CIK 0001048477
Entity typeother
Related Parties
1- filerCIK 0001380710
Filing Metadata
- Form type
- 4
- Filed
- May 5, 8:00 PM ET
- Accepted
- May 6, 4:45 PM ET
- Size
- 10.3 KB